<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02289729</url>
  </required_header>
  <id_info>
    <org_study_id>P14-335</org_study_id>
    <nct_id>NCT02289729</nct_id>
  </id_info>
  <brief_title>Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa Intestinal Gel for the Treatment of Advanced Parkinson's Disease</brief_title>
  <acronym>ADEQUA</acronym>
  <official_title>Study on Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa Intestinal Gel for the Treatment of Advanced Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient reported outcomes (PRO) have become an important endpoint assessed in clinical
      trials. It is important to understand the relationship between medication and patients'
      symptomatology, quality of life and wellbeing. We predict Duodopa will significantly improve
      quality of life and emotional wellbeing compared to baseline in patients with advance
      Parkinson disease (APD) not well controlled with conventional treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Parkinson's disease quality of life questionnaire (PDQ-39)</measure>
    <time_frame>6 months</time_frame>
    <description>Specific quality of life questionnaire for PD patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in individual and global score of unified Parkinson's disease rating scale (UPDRS)</measure>
    <time_frame>From baseline to end on follow-up, approximately 6 months</time_frame>
    <description>Motor evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in a patient's non-motor symptoms</measure>
    <time_frame>From baseline to end of follow-up, approximately 6 months</time_frame>
    <description>Evaluation of non-motor symptoms measured by non-motor symptoms scale (NMSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in a patient's emotional wellbeing</measure>
    <time_frame>From baseline to end on follow-up, approximately 6 months</time_frame>
    <description>A patient's emotional wellbeing status measured by global mood score (Norris)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in a patient's treatment satisfaction</measure>
    <time_frame>From baseline to end on follow-up, approximately 6 months</time_frame>
    <description>The patient's treatment satisfaction with current treatment will be measured by the SATMED-Q questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in caregiver quality of life</measure>
    <time_frame>From baseline to end on follow-up, approximately 6 months</time_frame>
    <description>Description of the quality of life status of the caregiver of the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in a patient's apathy status</measure>
    <time_frame>From baseline to end of follow-up, approximately 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in a patient's fatigue status</measure>
    <time_frame>From baseline to end on follow-up, approximately 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in a patient's depression and anxiety status</measure>
    <time_frame>From baseline to end on follow-up, approximately 6 months</time_frame>
    <description>The anxiety and depression status of a patient will be measured by Beck depression and anxiety inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in burden disease status of the caregiver of APD patients</measure>
    <time_frame>From baseline to end of follow-up, approximately 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in caregiver depression and anxiety</measure>
    <time_frame>From baseline to end of follow-up, approximately 6 months</time_frame>
    <description>Description of depression and anxiety status of the caregiver of APD patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in work productivity status of the caregiver of APD patients</measure>
    <time_frame>From baseline to end of follow-up, approximately 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Duodopa patients</arm_group_label>
    <description>Naive patients to Duodopa</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Advanced Parkinson's Disease patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with advanced levodopa-responsive Parkinson's disease, with at least, 2 hours
             &quot;off&quot; time or 2 hours of dyskinesia based on clinician's/investigator's medical
             judgment

          -  Patients with advanced Parkinson's disease with severe motor fluctuations and
             dyskinesia when combination of conventional PD treatments was unable to satisfactory
             control symptoms.

          -  Patients with advanced Parkinson's disease who meet the criteria for use of
             Levodopa/Carbidopa Intestinal Gel (LCIG) established in the summary of product
             characteristics, Spanish Neurology Society (SEN) guidelines, local/regional
             directories (CCAA) or site's protocols for use of LCIG in common clinical practice.

          -  The decision to treat with LCIG is made by the physician prior to any decision to
             approach the patient to participate in this study.

          -  Patients with a cognitive level enough to complete the questionnaires, confirmed by a
             Mini-mental state examination (MMSE) score of at least 26 points, according to the
             recommendation of the Movement Disorder Society (MDS) task force on dementia in
             Parkinson's Disease (PD)

        Exclusion Criteria:

          -  LCIG's contraindications included in the Summary of Product Characteristics (product
             label)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesc Valldeoriola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134791</name>
      <address>
        <city>Almeria</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128564</name>
      <address>
        <city>Barcelona, Cataluna</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136824</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136823</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128571</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136826</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128566</name>
      <address>
        <city>Barcelona</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134792</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128568</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128570</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128556</name>
      <address>
        <city>Cadiz, Andalucia</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128560</name>
      <address>
        <city>Cadiz, Andalucia</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128584</name>
      <address>
        <city>Cartagena, Murcia</city>
        <zip>30200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128578</name>
      <address>
        <city>Elche, Alicante</city>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128558</name>
      <address>
        <city>Espana, Canarias</city>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134794</name>
      <address>
        <city>Ferrol</city>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128561</name>
      <address>
        <city>Granada, Andalucia</city>
        <zip>18013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 147524</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128562</name>
      <address>
        <city>Palma de Mallorca, Balearas</city>
        <zip>ï»¿07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128565</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128569</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134795</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136822</name>
      <address>
        <city>Seville</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128583</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134793</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128555</name>
      <address>
        <city>Zaragoza, Aragon</city>
        <zip>50010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128557</name>
      <address>
        <city>Zaragoza, Aragon</city>
        <zip>50010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2014</study_first_submitted>
  <study_first_submitted_qc>November 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2014</study_first_posted>
  <last_update_submitted>December 7, 2016</last_update_submitted>
  <last_update_submitted_qc>December 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duodopa</keyword>
  <keyword>Advanced Parkinson's Disease</keyword>
  <keyword>Levodopa/Carbidopa intestinal gel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 8, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

